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When treatment decisions are based purely on
clinicopathological factors, many women with estrogen
receptor-positive/human epidermal growth factor
receptor 2-negative cancers are overtreated. Gene
expression profiles are valuable clinical tools that stratify
the recurrence risk to identify patients most likely to
benefit from adjuvant systemic therapies. Building
upon greater understanding of tumor biology and
more rigorous approaches to validation (including
independent studies with a high level of evidence),
several second-generation multigene tests have been
developed. In the previous issue, Martin and colleagues
report the third clinical validation study for EndoPredict,
a distributed assay to assess risk of distant recurrences
in estrogen receptor-positive/human epidermal growth
factor receptor 2-negative women. The authors
confirm the assay’s independent prognostic value in
premenopausal and postmenopausal, node-positive
women treated with contemporary chemotherapy
followed by endocrine therapy. EndoPredict did not,
however, predict benefit from adding paclitaxel.
Predictive signatures for selecting among chemotherapy
regimens remain an area needing further development.ing tumor size and nodal status as the EPclin classifier iden-When treatment is based solely on clinicopathological risk
factors, many women with estrogen receptor-positive/
human epidermal growth factor receptor 2-negative
(ER+/HER2−) tumors are overtreated – subjected to
morbidity from cytotoxic chemotherapy for negligible
benefit. Identifying patients safely treated by endocrine* Correspondence: torsten@mail.ubc.ca
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2014therapy alone has driven the development of prognostic
gene expression assays.
In the previous issue, Martin and colleagues describe
the third clinical validation of EndoPredict (EP; Sividon
Diagnostics GmbH, Cologne, Germany) [1], a second-
generation multigene test trained to predict distant recur-
rence in ER+/HER2− tumors, and by extension the need
for adjuvant chemotherapy. EP was previously validated in
prospective–retrospective analyses of endocrine-treated
postmenopausal ER+/HER2− breast cancer patients in
two clinical trials (ABCSG-6 and ABCSG-8) [2].
Genomic-based assays developed from complex, high-
dimensional data are susceptible to overfitting. Clinical
validation must be performed in entirely independent
datasets using predefined, locked-down classifier algo-
rithms and analysis plans. Martin and colleagues’ study
exemplifies the rigor required by Simon and colleagues for
a formal prospective–retrospective study to contribute
to generating level IB evidence [3]. The authors present
EP validation results in ER+/HER2− patients from the
GEICAM/9906 clinical trial of node-positive women
treated with contemporary chemotherapy. The prognostic
ability of EP remains robust in this higher risk group, iden-
tifying a 10-year metastatic rate of 7% in the predefined EP
low-risk group (versus 30% in the high-risk group). Includ-
tifies a small (13%) but impressively low-risk cohort of
women who experienced no distant recurrences at 10 years.
As the whole of this cohort received chemotherapy, the
clinical utility of this finding (to avoid chemotherapy) is dif-
ficult to infer, although the 100% metastasis-free survival
in both the fluorouracil–epirubicin–cyclophosphamide and
the fluorouracil–epirubicin–cyclophosphamide–paclitaxel
randomized arms does imply no benefit from adding
paclitaxel.
The authors speculate that the EPclin low-risk group
(recurrence-free at 10 years) in this 5-year endocrine
therapy-treated population may identify women not
needing extended endocrine therapy, consistent with thetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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CAF, cyclophosphamide, doxorubicin, fluorouracil; CEF, cyclophosphamide, epirubicin, fluorouracil; CMF, cyclophosphamide, methotrexate and fluorouracil; DR , distant relapse-free survival; ER, estrogen receptor;
FDA, US Food and Drug Administration; FFPE, formalin-fixed paraffin-embedded; HER2, human epidermal growth factor receptor 2; H:I, HOXB13:IL17BR; IHC, im unohistochemistry; MGI, molecular grade index; N/A,
not applicable; pN0, pathological lymph node-negative; pN+, pathological lymph node-positive; ROR, risk of recurrence; RT-PCR, reverse transcription polymera chain reaction. Breast Cancer Index: bioTheranostics,
San Diego, CA, USA; EndoPredict: Sividon Diagnostics GmbH, Cologne, Germany; IHC4: MammaPrint: Agendia, Amsterdam, The Netherlands; Mammostrat: Clarient, Inc. liso Viejo, CA, USA; Oncotype: Genomic Health, Redwood
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preted cautiously given that only 16 of the 74 EPclin
low-risk patients had 10-year follow-up data. Both the
aTTom and ATLAS trials have shown that survival ben-
efits of extended hormonal therapy become more appar-
ent after year 10 [5,6].
Several multigene prognostic assays have now been de-
veloped for use in ER+/HER2− breast cancers. First-
generation assays including MammaPrint (MammaPrint:
Agendia, Amsterdam, The Netherlands) and Oncotype
DX (Oncotype: Genomic Health, Redwood City, CA, USA)
suffered from early methodological issues, most seriously a
failure to maintain rigorous separation between training
and validation sets, and inclusion of nonluminal and/or
HER2+ tumors in their training sets, thereby allowing these
high-risk tumors to skew outcome-related gene selection
away from the relevant patient group [7-9]. MammaPrint
was specifically trained around early relapse (within 5 years)
in node-negative women, most having received no adjuvant
systemic therapy, and has not been shown to predict late
recurrence outside the original training-validation cohort.
Oncotype DX heavily weighed the tamoxifen-only arm of
the NSABP-B20 trial in its training set, where most recur-
rences occurred within 5 years, and has diminished prog-
nostic ability beyond year 5 [10].
More recently, building upon biological and technical
advances and more rigorous approaches to validation,
second-generation multigene tests have been developed,
including the Breast Cancer Index (BCI: bioTheranostics,
San Diego, CA, USA), PAM50 (PAM50: NanoString
Technologies Inc., Seattle, WA, USA) and EP. The Breast
Cancer Index combines a molecular grade index (quanti-
fying tumor grade-associated genes) and a two-gene
ratio,HOXB13:IL17BR, related to estrogen signaling [11].
PAM50, unlike signatures trained around outcome, was
developed as a biological classifier of the major intrinsic
molecular subtypes of breast cancer [12]. These three
assays predict both early and late recurrences [4,10,13].
IHC4 and Mammostrat (Mammostrat: Clarient, Inc.,
Aliso Viejo, CA, USA) immunohistochemical panels are
also prognostic in early breast cancer [14,15]. IHC4 uses
standard pathology markers (ER, progesterone receptor,
HER2 and Ki67) to provide prognostic information com-
parable with Oncotype DX [14]. Immunohistochemical
staining and scoring does suffer from limited analytical
reproducibility, probably contributing to Martin and col-
leagues’ identification of low Ki67 scores (<14%; a pub-
lished cutoff point for good-prognosis luminal A tumors)
in a surprisingly high fraction (almost three-quarters) of
this node-positive cohort [16].
Each of these gene expression and immunohistochemical
panels identifies a good prognosis group that may not
need chemotherapy. Emerging evidence suggests that some
panels identify women at such low risk of late recurrencethat they may safely avoid extended endocrine therapy.
For high-risk women, however, the question is not one of
chemotherapy versus no chemotherapy, but rather a ques-
tion of which chemotherapy agent(s) will be most effective
for which patients – a true predictive indication. In Martin
and colleagues’ report, the EP score did not predict benefit
from adding weekly paclitaxel to fluorouracil–epirubicin–
cyclophosphamide chemotherapy. Outcome-trained sig-
natures from nonchemotherapy populations are unlikely
to predict between chemotherapy regimens; Table 1 sum-
marizes some relevant features of the referenced molecu-
lar signatures, including predictive studies.
What does the future hold for gene expression signa-
tures? Cheaper and faster next-generation sequencing
has been touted as the pinnacle of personalized medi-
cine, destined to render multigene expression assays
obsolete. However, the genetic complexity of tumors
(copy number variations, chromosome-scale structural
changes, thousands of mutations, epigenetic changes
and intratumoral genetic heterogeneity) is proving even
more complex than anticipated. Much as the increased
detail from electron microscopy never did replace light
microscopy for cancer diagnosis, the broader signatures
detected by representative gene expression profile as-
says, reflecting clinically significant patterns common
across many patients, are likely to remain relevant for
important treatment decisions.
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